1. Scrip
  2. >>Business
  3. >>Deals

AstraZeneca Pays Big To Get Into RSV

 
• By Elizabeth Cairns

The UK group buys its first vaccine company, Icosavax, with an eye to its platform technology.  

Vaccine_shutterstock_1272846445_620x413.jpg

Hats off to Icosavax, Inc. – $838m isn’t a bad payday for a company with a single clinical-stage candidate. The vaccine maker has been snapped up by AstraZeneca PLC, and the sizeable upfront payment shows how eager the UK giant is to enter the respiratory syncytial virus (RSV) space, where GSK and Pfizer precede it.

Key Takeways
  • AstraZeneca has bought Icosavax for $838m upfront and potentially $1

AstraZeneca has structured the deal with the lion’s share of the money – $15 per share in cash – upfront

More from Deals

More from Business

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.